{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:23:59Z","timestamp":1785461039477,"version":"3.56.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":43,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2023.100691","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T02:56:22Z","timestamp":1676343382000},"page":"100691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-6484","authenticated-orcid":false,"given":"Mariska Q.N.","family":"Hackert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia F.","family":"van Uden-Kraan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette J.","family":"Agterof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette W.G.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit E.P.J.","family":"Vriens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan J.B.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Geenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"van der Padt-Pruijsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewoudt M.W.","family":"van de Garde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2023.100691_bib0001","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for adverse events: results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2023.100691_bib0002","first-page":"1","article-title":"Real-world effectiveness of palbociclib versus clinical trial results in patients with advanced \/metastatic breast cancer that progressed on previous endocrine therapy","volume":"13","author":"Bui","year":"2019","journal-title":"Breast Cancer: Basic Clin. Res."},{"issue":"9","key":"10.1016\/j.ctarc.2023.100691_bib0003","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2023.100691_bib0004","first-page":"570","article-title":"Development and evaluation of a real-world outcomes-based tool to support informed clinical decision making in the palliative treatment of patients with metastatic NSCLC","volume":"5","author":"Cramer-van der Welle","year":"2021","journal-title":"Clin. Cancer Inform."},{"key":"10.1016\/j.ctarc.2023.100691_bib0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2023.100691_bib0006","unstructured":"European Medicines Agency. Ibrance, INN-palbociclib \u2013 WC500217196. Samenvatting van de productkenmerken. http:\/\/www.ema.europa.eu\/docs\/nl_NL\/document_library\/EPAR_-_Product_Information\/human\/003853\/WC500217196.pdf. Published 2016. Accessed June 24, 2020."},{"issue":"20","key":"10.1016\/j.ctarc.2023.100691_bib0007","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2023.100691_bib0008","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/curroncol29030145","article-title":"The impact of real-world alternative dosing strategies of palbociclib on progression-free survival in patients with metastatic breast cancer","volume":"29","author":"Fu","year":"2022","journal-title":"Current Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2023.100691_bib0009","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"issue":"16","key":"10.1016\/j.ctarc.2023.100691_bib0010","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2217\/fon-2020-1264","article-title":"CDK 4\/6 inhibitor in HR+\/HER2- advanced\/metastatic breast cancer: a systematic review of real-world evidence studies","volume":"17","author":"Harbeck","year":"2021","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2023.100691_bib0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ctarc.2023.100691_bib0012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.breast.2021.11.013","article-title":"Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer","volume":"60","author":"Ismail","year":"2021","journal-title":"Breast"},{"issue":"33","key":"10.1016\/j.ctarc.2023.100691_bib0013","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2023.100691_bib0014","doi-asserted-by":"crossref","first-page":"djx187","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2023.100691_bib0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-020-05793-1","article-title":"Impact of early dose intensity reduction of palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer","volume":"183","author":"Moftakhar","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2023.100691_bib0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-020-06082-7","article-title":"A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application","volume":"187","author":"Richardson","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2023.100691_bib0017","unstructured":"SONIA study. www.sonia-studie.nl. Accessed November 23, 2022."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100691_bib0018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/ejhpharm-2017-001329","article-title":"Pharmacotherapy within a learning healthcare system: rationale for the Dutch Santeon Farmadatabase","volume":"26","author":"Van de Garde","year":"2019","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.ctarc.2023.100691_bib0019","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in combination with fulvestrant in women with hormone receptor-positive \/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2023.100691_bib0020","series-title":"Tracking medicine: A Researchers' Quest to Understand Health Care","author":"Wennberg","year":"2010"},{"issue":"1","key":"10.1016\/j.ctarc.2023.100691_bib0021","article-title":"Geography and the debate over Medicare reform","volume":"21","author":"Wennberg","year":"2002","journal-title":"Health Aff."},{"issue":"1","key":"10.1016\/j.ctarc.2023.100691_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clbc.2019.06.010","article-title":"Progression-free survival for real-world use of palbociclib in hormone receptor-positive metastatic breast cancer","volume":"20","author":"Wilkie","year":"2020","journal-title":"Clin. Breast Cancer"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:34:33Z","timestamp":1762842873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294223000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":22,"alternative-id":["S2468294223000126"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100691","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100691"}}